Spelling suggestions: "subject:"ciclosporina"" "subject:"ciclosporine""
1 |
Cyclosporin A for pulmonary applications : a novel formulation approach /Eskandar, Fadi M. January 2004 (has links)
Thesis (doctoral)--Christian Albrechts University, Kiel, 2004.
|
2 |
Untersuchungen zur Therapie der idiopathischen Sebadenitis des Hundes mittels Cyclosporin A (NEORAL)Boss, Christina. Unknown Date (has links) (PDF)
Tierärztl. Hochsch., Diss., 2004--Hannover.
|
3 |
Pharmakologische, biochemische und immunhistochemische Untersuchungen zu organtoxischen Wirkungen von Cyclosporin A vornehmlich im Hinblick auf apoptotische Reaktionen /Angstwurm, Angela. January 2001 (has links)
Regensburg, Universität, Thesis (doctoral), 2001.
|
4 |
Rapamycin vs. Cyclosporin A : Auswirkungen auf Transplantatabstossung und Tumorwachstum im TiermodellRichter, Sebastian January 2009 (has links)
Regensburg, Univ., Diss., 2009.
|
5 |
Untersuchungen zum Mechanismus Cyclosporin-induzierter Cholestase an isolierten Ratten Hepatozyten Couplets mittels konfokaler Laser Zytometrie /Kiefer, Joachim. January 1997 (has links) (PDF)
Universiẗat, Diss.--Kaiserslautern, 1997.
|
6 |
Pathomechanismen und mögliche Beeinflussung der chronischen Nierenabstossung durch die Immunsuppressiva Cyclosporin A und Tacrolimus im Rattenmodell /Samuel, Andre. January 2000 (has links)
Berlin, Freie Universität, Thesis (doctoral), 2000.
|
7 |
Periodische Proteinurie beim nephrotischen Syndrom - Konsequenzen für die Therapie / Periodical proteinuria and neprotic syndrome - consequences for the therapieDeeb, Iyad January 2007 (has links) (PDF)
In einer Beobachtungsstudie an 20 Patienten mit fokal sklerosierender und membranöser Glomerulonephritis wurde der Effekt einer Therapie mit ACE- Hemmer, Methylprednisolon und Ciclosporin A über einen Zeitraum von bis zu 10 Jahren verfolgt. Die Effektivität der genannten Therapie ist in der Literatur gut dokumentiert. Die Studie beobachtet folgende neue, bislang nicht beschriebene Ergebnisse: 1. Das Ausmaß der Proteinurie beim nephrotischen Syndrom unterliegt einem 28-Tage-Zyklus. Als Arbeitshypothese nehmen wir zyklische Schwankungen in der Aktivität des Immunsystems an. 2. Die bislang gängige Praxis, das nephrotische Syndrom ein halbes Jahr lang oder allenfalls bis zur ersten Abnahme der Proteinurie zu therapieren bedarf einer Korrektur. Erst wenn die Periodizität der Proteinurie sistiert, kann die Therapie ausgeschlichen werden, ohne ein Rezidiv befürchten zu müssen. Auf jeden Fall muss wesentlich länger therapiert werden als gegenwärtig in der Literatur berichtet. 3. Vor allem Patienten der Kategorie mit sehr langem Intervall zwischen Erstmanifestation und Therapiebeginn bedürfen einer möglicherweise lebenslangen Therapie um kein Endstage Renal Failure zu erleiden. 4. Das bislang gültige therapeutische Fenster der Ciclosporin-A-Therapie von 80 – 120 ng/ml Talspiegel kann bei gutem Ansprechen auf 60 – 80 ng/ml reduziert werden ohne hohes Rezidivrisiko. / 20 patients with focal segmental glomerulosclerosis (FSGS) and membranous nephropathy (mGN) are examined in a clinical trial, concerning the effect of a combined therapy with ACE inhibitor, prednisolone and cyclosporine A in a period of 10 years. The efficiency of this therapy is well documented in literature. The trial recognizes the following yet unknown facts: 1. The level of proteinuria in nephrotic syndrome describes a 28 days cycle. We suppose a connection to the cyclic change of the immune system. 2. The common therapy of the nephrotic syndrome lasting a half year needs a change. The immunsuppressive therapy may only be reduced after the suspending of the cycles of the proteinuria, without risking a relapse. 3. A long period between the first symptoms and the beginning of the therapy is a bad prediction. 4. The common blood level of cyclosporine A of 80 - 120 ng/ml may be reduced to 60 - 80 ng/ml without risking a higher relapse rate.
|
8 |
Avaliação clínica do crescimento gengival induzido por Ciclosporina-A ou Tacrolimus em indivíduos transplantados renais na ausência de bloqueadores de canais de cálcio: estudo prospectivo de 12 meses / Clinical evaluation of the gingival overgrowth induced by Ciclosporine-A or Tacrolimus in kidney transplant recipients in the absence of calcium channel blockers: a 12-month prospective studySekiguchi, Ricardo Takiy 01 August 2012 (has links)
O crescimento gengival é um efeito colateral comum nos indivíduos que recebem transplante de órgão e estão sob terapia imunossupressora. O objetivo deste estudo foi avaliar prospectivamente a ocorrência e severidade do crescimento gengival induzido pelo tacrolimus ou ciclosporina-A, na ausência de bloqueadores de canais de cálcio em indivíduos transplantados renais. Participaram do estudo 64 indivíduos que passaram por cirurgia de transplante e receberam ciclosporina (n=33) ou tacrolimus (n=31) como droga imunossupressora principal. Eles foram avaliados em 5 momentos: pré-transplante, 1, 3, 6 e 12 meses após transplante. Em todas as avaliações foram coletados dados demográficos e parâmetros clínicos periodontais (distância da margem gengival à junção cemento-esmalte, profundidade clínica de sondagem, nível clínico de inserção, índice de placa, sangramento à sondagem, e crescimento gengival). O valor médio de crescimento gengival no grupo ciclosporina foi maior que no grupo tacrolimus após 1 (p=0,04), 3 (p=0,001), 6 (p=0,007) e 12 meses (p=0,001). O crescimento gengival clinicamente significante foi observado em 30,3% (10 sujeitos) no grupo ciclosporina e 12,9% (4 sujeitos) no grupo tacrolimus após o período de 12 meses. Porém, essa diferença não foi estatisticamente significante (p=0,56). Concluímos que apesar de não ter sido encontrada diferença significante na ocorrência de crescimento gengival clinicamente significante, a severidade no grupo ciclosporina foi maior que no grupo tacrolimus após 12 meses de terapia imunossupressora. / Gingival overgrowth (GO) is a common side effect in recipients of organ transplants that are under immunosuppressive therapy. The aim of this study was to assess prospectively the occurrence and severity of gingival overgrowth induced by tacrolimus (Tcr) or ciclosporin A (CiA), in the absence of calcium channel blockers, in renal transplant patients. Sixty-four individuals undergoing transplantation received as the main immunosuppressant CiA (n=33) or Tcr (n=31). They were assessed at five time intervals: pre-transplant, 1, 3, 6, and 12 months after transplant. Demographic data and periodontal clinical parameters (cement-enamel junction to the gingival margin, probing depth, clinical attachment level, plaque index, bleeding on probing, and GO) were measured at all time intervals. The mean GO scores in CiA group were higher than Tcr group after 1 (p=0.04), 3 (p=0.001), 6 (p=0.007) and 12 months (p=0.001). A clinically significant GO was observed in 30.3% (10 subjects) in CiA group, and 12.9% (4 subjects) in Tcr group after 12 months. However, this difference was not significant (p=0.56). Although there was no significant difference in the occurrence of clinically significant GO, the severity in CiA group was higher than in Tcr group after 12 months of immunosuppressive therapy.
|
9 |
Avaliação longitudinal do crescimento gengival induzido por Ciclosporina A (CsA) e Tacrolimus, na ausência de bloqueadores de canal de cálcio, em indivíduos transplantados renais / Longitudinal evaluation of gingival overgrowth induced by Cyclosporin A (CsA) and Tacrolimus, in the absence of calcium channel blockers, in kidney transplant patientsPaixão, Caroline Gomes 29 September 2010 (has links)
Este estudo teve como objetivo avaliar longitudinalmente a incidência e severidade do crescimento gengival (CG) induzido por agentes imunossupressores, tacrolimus (Tcr) e ciclosporina-A (CsA), na ausência de bloqueadores de canal cálcio, em indivíduos transplantados renais. Foram avaliados 49 sujeitos transplantados renais, divididos em: grupo CsA (n=25) e grupo Tcr (n=24). Os indivíduos foram avaliados em quatro momentos: prétransplante, 30, 90 e 180 dias após o transplante renal. Os dados demográficos, parâmetros clínicos (IP, JEC-MG, PCS, NCI, SS e ICG) foram coletados em todos os momentos. A média do índice de crescimento gengival (ICG) foi significativamente menor no grupo Tcr comparado com grupo CsA após 30 dias (p=0,03), 90 dias (p=0,004) e 180 dias (p=0,01) de terapia imunossupressora. Decorridos 180 dias após o transplante renal, o crescimento gengival clinicamente significante foi observado em 20% dos sujeitos do grupo CsA e 8,3% dos sujeitos grupo Tcr. Porém, essa diferença não foi estatisticamente significante (p = 0,41). Para os parâmetros clínicos periodontais houve uma redução, em relação ao tempo de terapia imunossupressora, para o IP e SS (p<0,001) em ambos os grupos. Apesar de não apresentar diferença estatística na incidência do crescimento gengival clinicamente significante após 180 dias de terapia imunossupressora, observou-se que para o grupo Tcr o crescimento gengival ocorreu de forma mais tardia e a severidade do crescimento gengival nos pacientes que faziam uso do Tcr foi menor que nos pacientes que faziam uso da CsA. / The aim of this study was to make a longitudinal evaluation of the incidence and severity of gingival overgrowth (GO) induced by immunosuppressive agents, such as tacrolimus (Tcr) and cyclosporin A (CsA), in the absence of calcium channel blockers, in renal transplant patients. This longitudinal study was conducted with 49 renal transplant patients, who were divided into: CsA group (n=25) and Tcr group (n=24). The individuals were assessed at four time intervals: before transplant, 30, 90 and 180 days after the renal transplant. The demographic data, clinical parameters (PI, CEJ-GM, PD, CAL, BOP and GOI) were collected at all times intervals. The gingival overgrowth index mean was significantly lower in Tcr group compared with CsA group after 30 days (p=0.03), 90 days (p=0.004) and 180 days (p=0.01) of immunosuppressive therapy. One hundred and eighty days after the renal transplant, clinically significant gingival overgrowth was observed in 20.0% of the individuals in CsA group and 8.3% of the individuals in Tcr group. However, this difference was not statistically significant (p = 0.41). There was a reduction of the periodontal clinical parameters as regards the time of immunosuppressive therapy for PI and BOP (p <0.001) in both groups. Although there was no statistical difference in the incidence of clinically significant gingival overgrowth after 180 days of immunosuppressive therapy, it was observed that for the Tcr group gingival overgrowth occurred later and the severity of gingival overgrowth in this group was lower than in patients who used CsA.
|
10 |
Avaliação longitudinal do crescimento gengival induzido por Ciclosporina A (CsA) e Tacrolimus, na ausência de bloqueadores de canal de cálcio, em indivíduos transplantados renais / Longitudinal evaluation of gingival overgrowth induced by Cyclosporin A (CsA) and Tacrolimus, in the absence of calcium channel blockers, in kidney transplant patientsCaroline Gomes Paixão 29 September 2010 (has links)
Este estudo teve como objetivo avaliar longitudinalmente a incidência e severidade do crescimento gengival (CG) induzido por agentes imunossupressores, tacrolimus (Tcr) e ciclosporina-A (CsA), na ausência de bloqueadores de canal cálcio, em indivíduos transplantados renais. Foram avaliados 49 sujeitos transplantados renais, divididos em: grupo CsA (n=25) e grupo Tcr (n=24). Os indivíduos foram avaliados em quatro momentos: prétransplante, 30, 90 e 180 dias após o transplante renal. Os dados demográficos, parâmetros clínicos (IP, JEC-MG, PCS, NCI, SS e ICG) foram coletados em todos os momentos. A média do índice de crescimento gengival (ICG) foi significativamente menor no grupo Tcr comparado com grupo CsA após 30 dias (p=0,03), 90 dias (p=0,004) e 180 dias (p=0,01) de terapia imunossupressora. Decorridos 180 dias após o transplante renal, o crescimento gengival clinicamente significante foi observado em 20% dos sujeitos do grupo CsA e 8,3% dos sujeitos grupo Tcr. Porém, essa diferença não foi estatisticamente significante (p = 0,41). Para os parâmetros clínicos periodontais houve uma redução, em relação ao tempo de terapia imunossupressora, para o IP e SS (p<0,001) em ambos os grupos. Apesar de não apresentar diferença estatística na incidência do crescimento gengival clinicamente significante após 180 dias de terapia imunossupressora, observou-se que para o grupo Tcr o crescimento gengival ocorreu de forma mais tardia e a severidade do crescimento gengival nos pacientes que faziam uso do Tcr foi menor que nos pacientes que faziam uso da CsA. / The aim of this study was to make a longitudinal evaluation of the incidence and severity of gingival overgrowth (GO) induced by immunosuppressive agents, such as tacrolimus (Tcr) and cyclosporin A (CsA), in the absence of calcium channel blockers, in renal transplant patients. This longitudinal study was conducted with 49 renal transplant patients, who were divided into: CsA group (n=25) and Tcr group (n=24). The individuals were assessed at four time intervals: before transplant, 30, 90 and 180 days after the renal transplant. The demographic data, clinical parameters (PI, CEJ-GM, PD, CAL, BOP and GOI) were collected at all times intervals. The gingival overgrowth index mean was significantly lower in Tcr group compared with CsA group after 30 days (p=0.03), 90 days (p=0.004) and 180 days (p=0.01) of immunosuppressive therapy. One hundred and eighty days after the renal transplant, clinically significant gingival overgrowth was observed in 20.0% of the individuals in CsA group and 8.3% of the individuals in Tcr group. However, this difference was not statistically significant (p = 0.41). There was a reduction of the periodontal clinical parameters as regards the time of immunosuppressive therapy for PI and BOP (p <0.001) in both groups. Although there was no statistical difference in the incidence of clinically significant gingival overgrowth after 180 days of immunosuppressive therapy, it was observed that for the Tcr group gingival overgrowth occurred later and the severity of gingival overgrowth in this group was lower than in patients who used CsA.
|
Page generated in 0.0548 seconds